相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
Hsiling Chiu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-1. Follicular lymphoma (FL)
Koji Izutsu
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
F. Morschhauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma
Barbara Kiesewetter et al.
BLOOD (2017)
TREATMENT WITH COMBINATION OF LENALIDOMIDE AND RITUXIMAB ACHIEVES DURABLE RESPONSES IN A LONG TERM FOLLOW UP OF PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA
M. Chaudhry et al.
HEMATOLOGICAL ONCOLOGY (2017)
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)
P. Martin et al.
ANNALS OF ONCOLOGY (2017)
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2016)
Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006
Dai Chihara et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Differences in incidence and trends of haematological malignancies in Japan and the United States
Dai Chihara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma
Joseph M. Tuscano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
Nathan H. Fowler et al.
LANCET ONCOLOGY (2014)
Treatment of Follicular Lymphoma
Koji Izutsu
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2014)
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2013)
Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study
Emanuele Zucca et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy
Luca Arcaini et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Prognostic Assessment in Patients with Indolent B-Cell Lymphomas
Luca Arcaini et al.
SCIENTIFIC WORLD JOURNAL (2012)
Rituximab in Indolent Lymphomas
Tarek Sousou et al.
SEMINARS IN HEMATOLOGY (2010)
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
Alan G. Ramsay et al.
BLOOD (2009)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Tumour lysis syndrome: new therapeutic strategies and classification
MS Cairo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Re-treatment of relapsed indolent B-cell lymphoma with rituximab
T Igarashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2001)
分享论文
